Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation

Haematologica. 2019 Nov;104(11):2155-2163. doi: 10.3324/haematol.2019.223073. Epub 2019 Aug 29.


Of the two human herpesvirus 6 (HHV-6) species, human herpesvirus 6B (HHV-6B) encephalitis is an important cause of morbidity and mortality after allogeneic hematopoietic stem cell transplant. Guidelines for the management of HHV-6 infections in patients with hematologic malignancies or post-transplant were prepared a decade ago but there have been no other guidelines since then despite significant advances in the understanding of HHV-6 encephalitis, its therapy, and other aspects of HHV-6 disease in this patient population. Revised guidelines prepared at the 2017 European Conference on Infections in Leukaemia covering diagnosis, preventative strategies and management of HHV-6 disease are now presented.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Cell Transformation, Viral
  • Combined Modality Therapy
  • Europe
  • Graft vs Host Disease / etiology
  • Hematologic Neoplasms / complications*
  • Hematologic Neoplasms / diagnosis
  • Hematologic Neoplasms / therapy
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Hematopoietic Stem Cell Transplantation / methods
  • Herpesvirus 6, Human*
  • Humans
  • Immunocompromised Host
  • Practice Guidelines as Topic*
  • Roseolovirus Infections / diagnosis*
  • Roseolovirus Infections / etiology*
  • Roseolovirus Infections / therapy*
  • Treatment Outcome


  • Antiviral Agents